期刊
TISSUE ANTIGENS
卷 78, 期 3, 页码 203-207出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1399-0039.2011.01709.x
关键词
adjuvant; allogeneic vaccine; HLA; HLA-B35; immunotherapy; metastatic melanoma
资金
- Perlstein Family
- Adelson Medical Research Foundation
- Israel Cancer Association
This work presents survival data of 42 melanoma patients at high risk for disease recurrence who received an allogeneic melanoma vaccine composed of three cell lines, each matching at least one allele of the recipient's human leukocyte antigen (HLA)-A and -B loci. The 5-year overall survival (OS) rate and disease-free survival (DFS) compared favorably with the standard interferon-alpha regimen. Interestingly, patients bearing HLA-B35 had significantly better OS and DFS (OS of 100% and DFS of 90% for HLA-B35 vs 56% and 23%, for the non-B35 patients). In contrast, patients expressing HLA-B07 did not fare well with the vaccine. Although the data include a relatively small cohort of patients, it strongly hints toward a correlation between HLA types and potential benefit from anticancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据